This clinical trial previously demonstrated that adding enzalutamide ... in a well-defined cohort of patients resembling the EMBARK trial population that was supposed to only include those ...

Opens in a new tab or window SAN FRANCISCO -- The addition of radionuclide therapy with 177 Lu-PSMA-617 (Pluvicto) to enzalutamide (Xtandi) improved overall survival (OS) in patients with ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN FRANCISCO -- Adding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration ...

Adding talazoparib to enzalutamide led to a statistically significant and clinically meaningful improvement in overall survival in patients with metastatic castration-resistant prostate cancer ...

Researchers conducted a retrospective study using data from 182 subjects with high-risk recurrent prostate cancers who were eligible for the EMBARK ... that adding enzalutamide to androgen ...